# AusperBio

**Canonical:** https://apis.io/providers/ausperbio/  
**Website:** https://www.ausperbio.com/  
**APIs profiled:** 0

AusperBio — AusperBio Therapeutics, Inc. in the United States and Ausper Biopharma Co., Ltd. (杭州浩博医药有限公司) in Hangzhou, China — is a clinical-stage biopharmaceutical company founded in 2019 that develops oligonucleotide and targeted delivery technologies, with an initial focus on achieving a functional cure for chronic hepatitis B infection. Its proprietary Med-Oligo antisense oligonucleotide (ASO) platform pairs novel ASO design and optimization with targeted delivery conjugation chemistry, and its Au-HALO hepatocyte-targeting delivery technology extends the same modular approach to siRNA. The lead candidate AHB-137 is an unconjugated ASO that completed enrollment in two Phase II trials and received China CDE clearance to enter Phase III; a second clinical candidate, AHB-171, is a hepatocyte-targeted siRNA. The company has raised more than $200M across Series B, B+ and B2 rounds from investors including Qiming Venture Partners, HanKang Capital, CDH Investments, Sherpa Capital, YuanBio Venture Capital and Genesis Capital. AusperBio sells therapeutics, not software: it publishes no developer program, no public API, no SDK and no machine-readable API contract. Its only machine-readable surface is the private Spring Boot CMS backend that renders ausperbio.com, whose springdoc API description is correctly locked behind authentication.

## Kin Score — 4.1 / 100 (minimal)

Scored 2026-08-19 under rubric 0.12.0. Trend: falling (-8.1 from 12.2).

| Facet | Score |
|---|---|
| Discoverability | 57.4 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Security (1)

- **Ausperbio Domain Security** — TLSv1.3 · HSTS

## Tags

Company, Biotechnology, Pharmaceuticals, Biopharmaceutical, Life Sciences, Therapeutics, Oligonucleotide, Antisense Oligonucleotide, siRNA, Clinical Trials, Hepatitis B, Drug Development, Health, China

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/ausperbio/). Scores are computed from the provider's own public artifacts under a published rubric.